On the other hand, at later stages in the evolution of tauopathies, such as dominantly inherited AD, an elevation in cerebrospinal fluid tau coincides with drastic changes in cognitive scores during the transition to the clinical presentation of the disease (McDade et al., 2018). This evidence concerns the gene MAPT and Alzheimer disease.